The implications of this finding are far reaching, as therapeutic targeting of EGFR in NSCLC has revolutionized patient care, greatly extending survival times over chemotherapy, although drug resistance remains a challenge (5). This evidence concerns the gene EGFR and non-small cell lung carcinoma.